176 related articles for article (PubMed ID: 29757322)
1. Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension.
Hudgens S; Evans C; Phillips E; Hill M
J Patient Rep Outcomes; 2017; 1(1):3. PubMed ID: 29757322
[TBL] [Abstract][Full Text] [Related]
2. Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.
Dellon ES; Collins MH; Katzka DA; Hudgens S; Lan L; Williams J; Vera-Llonch M; Hirano I
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):699-706.e4. PubMed ID: 32272243
[TBL] [Abstract][Full Text] [Related]
3. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
Dellon ES; Katzka DA; Collins MH; Hamdani M; Gupta SK; Hirano I;
Gastroenterology; 2017 Mar; 152(4):776-786.e5. PubMed ID: 27889574
[TBL] [Abstract][Full Text] [Related]
4. Qualitative assessment of the suitability of the Dysphagia Symptom Questionnaire to monitor dysphagia in children aged 7-10 years with eosinophilic esophagitis.
Pokrzywinski RM; Goodwin B; Dellon ES; Kodroff E; Brooks A; Bailey A; Williams J; Desai NK
J Patient Rep Outcomes; 2023 Oct; 7(1):110. PubMed ID: 37906323
[TBL] [Abstract][Full Text] [Related]
5. Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.
Hirano I; Collins MH; Katzka DA; Mukkada VA; Falk GW; Morey R; Desai NK; Lan L; Williams J; Dellon ES;
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):525-534.e10. PubMed ID: 33887475
[TBL] [Abstract][Full Text] [Related]
6. Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.
Mukkada VA; Gupta SK; Gold BD; Dellon ES; Collins MH; Katzka DA; Falk GW; Williams J; Zhang W; Boules M; Hirano I; Desai NK
J Pediatr Gastroenterol Nutr; 2023 Dec; 77(6):760-768. PubMed ID: 37718471
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
Dellon ES; Woosley JT; Arrington A; McGee SJ; Covington J; Moist SE; Gebhart JH; Tylicki AE; Shoyoye SO; Martin CF; Galanko JA; Baron JA; Shaheen NJ
Gastroenterology; 2019 Jul; 157(1):65-73.e5. PubMed ID: 30872104
[TBL] [Abstract][Full Text] [Related]
8. Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis.
Dellon ES; Irani AM; Hill MR; Hirano I
Aliment Pharmacol Ther; 2013 Sep; 38(6):634-42. PubMed ID: 23837796
[TBL] [Abstract][Full Text] [Related]
9. Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses From a 12-Week, Phase 2, Randomized, Placebo-controlled Trial.
Collins MH; Dellon ES; Katzka DA; Hirano I; Williams J; Lan L
Am J Surg Pathol; 2019 Nov; 43(11):1501-1509. PubMed ID: 31498177
[TBL] [Abstract][Full Text] [Related]
10. Validation of the novel Eosinophilic Esophagitis Impact Questionnaire.
McCann E; Chehade M; Spergel JM; Yaworsky A; Symonds T; Stokes J; Tilton ST; Sun X; Kamat S
J Patient Rep Outcomes; 2023 Nov; 7(1):120. PubMed ID: 38010430
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis.
Warners MJ; Hindryckx P; Levesque BG; Parker CE; Shackelton LM; Khanna R; Sandborn WJ; D'Haens GR; Feagan BG; Bredenoord AJ; Jairath V
Am J Gastroenterol; 2017 Nov; 112(11):1658-1669. PubMed ID: 29039850
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Severity and the Remission Criteria in Eosinophilic Esophagitis.
Maslenkina K; Mikhaleva L; Mikhalev A; Kaibysheva V; Atiakshin D; Motilev E; Buchwalow I; Tiemann M
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137426
[TBL] [Abstract][Full Text] [Related]
14. Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease.
Martin LJ; Franciosi JP; Collins MH; Abonia JP; Lee JJ; Hommel KA; Varni JW; Grotjan JT; Eby M; He H; Marsolo K; Putnam PE; Garza JM; Kaul A; Wen T; Rothenberg ME
J Allergy Clin Immunol; 2015 Jun; 135(6):1519-28.e8. PubMed ID: 26051952
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Swedish Watson Dysphagia Scale for adult patients with eosinophilic esophagitis.
Albinsson S; Tuomi L; Wennerås C; Larsson H
Dis Esophagus; 2022 Jul; 35(7):. PubMed ID: 35066581
[TBL] [Abstract][Full Text] [Related]
16. Heartburn and dyspepsia symptom severity improves after treatment and correlates with histology in adults with eosinophilic esophagitis.
Eluri S; Perjar I; Betancourt R; Randall C; Raja S; Woosley JT; Shaheen NJ; Dellon ES
Dis Esophagus; 2019 Nov; 32(9):. PubMed ID: 31329864
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis.
Dellon ES; Katzka DA; Collins MH; Gupta SK; Lan L; Williams J; Hirano I
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):666-673.e8. PubMed ID: 29902649
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
Lucendo AJ; Miehlke S; Schlag C; Vieth M; von Arnim U; Molina-Infante J; Hartmann D; Bredenoord AJ; Ciriza de Los Rios C; Schubert S; Brückner S; Madisch A; Hayat J; Tack J; Attwood S; Mueller R; Greinwald R; Schoepfer A; Straumann A;
Gastroenterology; 2019 Jul; 157(1):74-86.e15. PubMed ID: 30922997
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab Improves Health-Related Quality of Life and a Range of Symptoms in Patients With Eosinophilic Esophagitis.
Spergel JM; Chehade M; Dellon ES; Bredenoord AJ; Sun X; Glotfelty L; Shabbir A; Tilton ST; McCann E
Am J Gastroenterol; 2024 Jun; ():. PubMed ID: 38940435
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcome measures in dysphagia: a systematic review of instrument development and validation.
Patel DA; Sharda R; Hovis KL; Nichols EE; Sathe N; Penson DF; Feurer ID; McPheeters ML; Vaezi MF; Francis DO
Dis Esophagus; 2017 May; 30(5):1-23. PubMed ID: 28375450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
